Billionaire investor Leon Cooperman gave 12 stock recommendations at the Delivering Alpha conference Wednesday.» Read More
Oct 1- Watson Pharmaceuticals Inc:. *Confirms favorable district court ruling in androgelï¿ ½ 1% antitrust litigation. *Says court found that the plaintiffs' claims were unsustainable.
BRUSSELS, Oct 1- The following are mergers under review by the European Commission and a brief guide to the EU merger process:. --Private equity firms Carlyle and BC Partners to acquire U.S. industrial pumps maker Hamilton Sundstrand Industrial which is owned by United Technologies Corp.
Not everyone has the kind of capital Leon Cooperman has to buy stocks. From his 10 top picks, the Fast traders reveal their single favorites.
Check out which companies are making headlines after the bell Wednesday:
Take a look at some of Monday’s morning movers:
Although Watson Pharmaceuticals’ acquisition of Swiss generic drug maker Actavis was expected for over a month, a strong reaction to Wednesday’s deal shows that analysts are hooked on the drugmaker.
Take a look at some of Thursday's morning movers.
Check out which companies are making headlines after-the-bell Wednesday:
Earlier in the trading session, eBay shares were up as much as 16.6 percent, their best intraday gain since Oct. 2008.
Stocks in the S&P 1,500 displaying unusual volume in Thursday's trading session.
Stocks ended narrowly mixed in a lackluster session Wednesday following a weaker-than-expected existing home sales report and as investors were reluctant to jump in following the recent market rally.
Some of the steadiest growth stocks lie in pharmaceuticals and agricultural plays, one noted investor said Thursday.
Generic medicines accounted for over 75% of prescriptions dispensed by retail drug stores in 2010. And today that number keeps growing. Paul Bisaro, Watson Pharmaceuticals CEO, provides industry perspective.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Take a look at some of Monday morning's early movers:
Stocks closed narrowly mixed in lackluster trading Tuesday, with the S&P breaking a 5-day winning streak, as Greece's failed debt restructuring negotiations and a handful of tepid earnings reports weighed on the market.
U.S. stock index futures pointed to a lower open Tuesday as concerns about the European debt crisis continued to weigh and as investors digested a handful of mixed corporate earnings reports.
Discussing whether Pfizer doing enough to replace the lost revenue from Lipitor, with Tim Chiang, CRT Capital Group, and Catherine Arnold, Credit Suisse. They also discuss what a restructured Pfizer look like in 2012.
What follows is a look at stocks in the S&P 1,500 displaying unusual volume in Wednesday's trading session.
For the last year, Pfizer has been laying the groundwork to combat the looming competition against Lipitor, forging deals with insurers, pharmacy benefit managers and patients to meet or beat the price of its generic replacements, the New York Times reports.